Dxd-d5

Dxd-d5 is a deuterium labeled Dxd. Dxd is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a) [1].

Product Specifications

Product Name Alternative

Exatecan-d5 derivative for ADC

UNSPSC

12352005

Hazard Statement

H301

Target

ADC Payload; Topoisomerase

Type

Isotope-Labeled Compounds

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Concentration

10mM

Purity

98.89

Solubility

DMSO : ≥ 40mg/mL

Smiles

O=C1[C@](O)(C(C([2H])([2H])[2H])([2H])[2H])C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5NC(CO)=O)C(C)=C(F)C=C6N=C4C3=C2)=O

Molecular Formula

C26H19D5FN3O6

Molecular Weight

498.51

Precautions

H301

References & Citations

[1]Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22 (20) :5097-5108.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.